Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 24, 2012, Pages 9499-9504

  Kong, Leopold ^a   Giang, Erick ^a   Robbins, Justin B ^a   Stanfield, Robyn L ^a   Burton, Dennis R ^a,b   Wilson, Ian A ^a   Law, Mansun ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

Antigen antibody complex; Neutralizing determinant; Protective determinant; Type I' turn

Indexed keywords

ASPARAGINE; ASPARTIC ACID; EPITOPE; HCV1 MONOCLONAL ANTIBODY; LEUCINE; NEUTRALIZING ANTIBODY; SERINE; TRYPTOPHAN; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN;

ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; GENOTYPE; HEPATITIS C VIRUS; HUMAN; HYDROGEN BOND; HYDROPHILICITY; HYDROPHOBICITY; LIGHT CHAIN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; VACCINATION; VIRUS ENVELOPE; VIRUS MORPHOLOGY; VIRUS NEUTRALIZATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEUTRALIZING; EPITOPES; HEPACIVIRUS; IMMUNE EVASION; MODELS, ANIMAL; MOLECULAR SEQUENCE DATA; PAN TROGLODYTES; PROTEIN CONFORMATION; VIRAL VACCINES;

EID: 84862177880     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1202924109     Document Type: Article

References (46)

1. Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5:558-567. (Pubitemid 41196755)
2. Miller FD, Abu-Raddad LJ (2010) Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. Proc Natl Acad Sci USA 107:14757-14762.
3. Wasley A, Miller JT, Finelli L; Centers for Disease Control and Prevention (CDC) (2007) 0Surveillance for acute viral hepatitis-United States, 2005. MMWR Surveill Summ 56: 1-24.
4. Onofrey S, et al.; Centers for Disease Control and Prevention (CDC) (2011) Hepatitis C virus infection among adolescents and young adults: Massachusetts, 2002-2009. MMWR Morb Mortal Wkly Rep 60:537-541.
5. Lemon SM, Walker C, Alter MJ, Yi M (2007) Hepatitis C Virus. Virology, eds Knipe DM, et al. (Lippincott-Raven, Philadelphia), 5th Ed, Vol 1, pp 1253-1304.
6. Galossi A, Guarisco R, Bellis L, Puoti C (2007) Extrahepatic manifestations of chronic HCV infection. J Gastrointestin Liver Dis 16:65-73. (Pubitemid 46548592)
7. Ciesek S, Manns MP (2011) Hepatitis in 2010: The dawn of a new era in HCV therapy. Nat Rev Gastroenterol Hepatol 8:69-71.
8. Gane E (2011) Future hepatitis C virus treatment: Interferon-sparing combinations. Liver Int 31(Suppl 1):62-67.
9. Houghton M, Abrignani S (2005) Prospects for a vaccine against the hepatitis C virus. Nature 436:961-966. (Pubitemid 41191672)
10. Halliday J, Klenerman P, Barnes E (2011) Vaccination for hepatitis C virus: Closing in on an evasive target. Expert Rev Vaccines 10:659-672.
11. Kuiken C, Simmonds P (2009) Nomenclature and numbering of the hepatitis C virus. Methods Mol Biol 510:33-53.
12. Neumann AU, et al. (1998) Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282:103-107. (Pubitemid 28471138)
13. Owsianka A, et al. (2005) Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol 79:11095-11104. (Pubitemid 41170650)
14. Flint M, et al. (1999) Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol 73:6235-6244. (Pubitemid 29327798)
15. Broering TJ, et al. (2009) Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. J Virol 83:12473-12482.
16. Keck ZY, et al. (2008) Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies. J Virol 82: 6061-6066.
17. Johansson DX, et al. (2007) Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. Proc Natl Acad Sci USA 104:16269-16274. (Pubitemid 350099395)
18. Schofield DJ, et al. (2005) Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity. Hepatology 42: 1055-1062. (Pubitemid 43112672)
19. Law M, et al. (2008) Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 14:25-27.
20. Zhang P, et al. (2007) Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc Natl Acad Sci USA 104:8449-8454. (Pubitemid 47175508)
21. Tarr AW, et al. (2012) Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization. J Virol 86:2739-2749.
22. Tarr AW, et al. (2007) Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33. J Gen Virol 88:2991-3001. (Pubitemid 350131236)
23. Blair BM, et al. (2009) A novel human monoclonal antibody directed against the E2 glycoprotein of hepatitis C virus (HCV) prevents infection in chimpanzees. J Hepatol 50:S381.
24. Krey T, et al. (2010) The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule. PLoS Pathog 6:e1000762.
25. Yagnik AT, et al. (2000) A model for the hepatitis C virus envelope glycoprotein E2. Proteins 40:355-366. (Pubitemid 30624444)
26. Helle F, Duverlie G, Dubuisson J (2011) The hepatitis C virus glycan shield and evasion of the humoral immune response. Viruses 3:1909-1932.
27. Martin AC (1996) Accessing the Kabat antibody sequence database by computer. Proteins 25:130-133.
28. Hutchinson EG, Thornton JM (1994) A revised set of potentials for beta-turn formation in proteins. Protein Sci 3:2207-2216.
29. Folgori A, et al. (2006) A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 12:190-197. (Pubitemid 43214745)
30. Elmowalid GA, et al. (2007) Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci USA 104: 8427-8432. (Pubitemid 47175504)
31. Choo QL, et al. (1994) Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA 91:1294-1298.
32. Farci P, et al. (1996) Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci USA 93:15394-15399.
33. Rosa D, et al. (1996) A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: Cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci USA 93:1759-1763. (Pubitemid 26079830)
34. Esumi M, Zhou YH, Tanoue T, Tomoguri T, Hayasaka I (2002) In vivo and in vitro evidence that cross-reactive antibodies to C-terminus of hypervariable region 1 do not neutralize heterologous hepatitis C virus. Vaccine 20:3095-3103.
35. Gal-Tanamy M, et al. (2008) In vitro selection of a neutralization- resistant hepatitis C virus escape mutant. Proc Natl Acad Sci USA 105:19450-19455.
36. Dhillon S, et al. (2010) Mutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies. J Virol 84:5494-5507.
37. Kim DE, Chivian D, Baker D (2004) Protein structure prediction and analysis using the Robetta server. Nucleic Acids Res 32(Web Server issue):W526-W531.
38. Dormitzer PR, Ulmer JB, Rappuoli R (2008) Structure-based antigen design: A strategy for next generation vaccines. Trends Biotechnol 26:659-667.
39. Giang E, et al. (2012) Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci USA 109:6205-6210.
40. Kwong PD, Wilson IA (2009) HIV-1 and influenza antibodies: Seeing antigens in new ways. Nat Immunol 10:573-578.
41. Sui J, et al. (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16:265-273.
42. Ekiert DC, et al. (2011) A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333:843-850.
43. McLellan JS, et al. (2011) Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480:336-343.
44. Pejchal R, et al. (2011) A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334:1097-1103.
45. Newman J, et al. (2005) Towards rationalization of crystallization screening for small-to medium-sized academic laboratories: the PACT/JCSG+ strategy. Acta Crystallogr D Biol Crystallogr 61:1426-1431. (Pubitemid 43943144)
46. Dubuisson J, et al. (1994) Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses. J Virol 68:6147-6160. (Pubitemid 24294864)